Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;23(12):2222-32.
doi: 10.1038/leu.2009.179. Epub 2009 Sep 10.

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

J P Laubach  1 , A Mahindra, C S Mitsiades, R L Schlossman, N C Munshi, I M Ghobrial, N Carreau, T Hideshima, K C Anderson, P G Richardson
Affiliations
Review

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

J P Laubach et al. Leukemia. 2009 Dec.

Abstract

Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

JP Laubach: Advisory Board Novartis Pharmaceuticals. CS Mitsiades: Consultant Millennium Pharmaceuticals, Novartis Pharmaceuticals, and Kosan Pharmaceuticals. RL Schlossman: Speakers Bureau Celgene Corporation and Millennium Pharmaceuticals. IM Ghobrail: Speakers Bureau Celgene Corporation, Millennium Pharmaceuticals, and Novartis Pharmaceuticals. KC Anderson: Advisory Board Celgene Corporation, Millennium Pharmaceuticals; Consultant Celgene Corporation and Millennium Pharmaceuticals. PG Richardson: Advisory Board Celgene Corporation, Millennium Pharmaceuticals; Speakers Bureau Celgene Corporation, Millennium Pharmaceuticals. Research support was provided by Celegene Corporation, Millennium Pharmaceuticals.

References

    1. Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8–11. - PubMed
    1. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia. 1995;9:2115–2118. - PubMed
    1. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med. 1984;310:1353–1356. - PubMed
    1. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer. 1995;71:326–330. - PMC - PubMed
    1. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1995;18:475–480. - PubMed

Publication types

MeSH terms